A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.

ABSTRACT: Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved in the last years due to development and clinical approval of highly effective agents including immune checkpoint inhibitors (ICIs) and oncogene-directed therapies. Molecular profiling of lung cancer samples for activated oncogenes, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and BRAF, is routinely performed to select the most appropriate up-front treatment. However, the identification of new therapeutic targets remains a high priority. Recently, MET exon 14 skipping mutations have emerged as novel actionable oncogenic alterations in NSCLC, sensitive to MET inhibition. In this review we discuss: (I) MET ge

SUBMITTER: Santarpia M 

PROVIDER: S-EPMC8044480 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature